Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec’s Reports Of Tysabri Side Effects Don’t Rattle FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Wall Street reacted sharply to disclosure of two new PML cases associated with Tysabri, but it doesn’t sound like FDA plans a regulatory response.

You may also be interested in...



FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use

FDA appears to be setting new policy on when drugs should be available for compassionate use

FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use

FDA appears to be setting new policy on when drugs should be available for compassionate use

FDA Still Behind Tysabri Monotherapy

Medwatch warning is less strident than some feared.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel